This press release doesn’t change the fact that Leronlimab binds to CCR5. And as much as I wanted to see the date for HIV approval get set, the main reason was for me was credibility. I believe it will still occur. How could it not with such significant improvements over current therapies and such a benign safety profile? Ok, so that comes later. The FDA kicked the can further down the road. I can live with that because it’s just more time. Thankfully, we are about to be legitimized in an even bigger way with the mild to moderate Covid trial results, slated to be unblinded this week. That will stamp this company with all the credibility it needs, and won’t be too shabby when it comes to share price either. I’m annoyed but resolute.